Orasure Technologies Inc (OSUR)
| Market Cap | $238.90M+64.0% |
| Revenue (ttm) | $116.23M |
| Net Income | -$48.51M |
| EPS | -$0.69 |
| Shares Out | 69.05M |
| PE Ratio | n/a |
| Forward PE | -7.21 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 502,791 |
| Open | $3.57 |
| Previous Close | $3.61 |
| Day's Range | $3.40 - $3.61 |
| 52-Week Range | $2.28 - $4.58 |
| Beta | 1.06 |
| Analysts | Buy |
| Price Target | $5.50(+58.96%) |
| Earnings Date | Nov 9, 2026 |
About OSUR
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of urine samples; and HEMAcollect protein blood collection device. In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. It sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, and companion animal, markets. The company was founded in 1987 and is headquartered in Bethlehem, Pennsylvania.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$OSUR stock is featured in our Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of OSUR by members of U.S. Congress
| Tom MalinowskiHouse | Sale$15.00K – $50.00K | Feb 23, 2021 |
| Tom MalinowskiHouse | Sale$1.00K – $15.00K | Jan 11, 2021 |
| Tom MalinowskiHouse | Sale$15.00K – $50.00K | Dec 9, 2020 |
| Tom MalinowskiHouse | Sale$15.00K – $50.00K | Oct 7, 2020 |
Recently reported changes in OSUR holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by OSUR's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
OSUR Estimated quarterly lobbying spending
Source: U.S. Senate LDA
OSUR Revenue by Segment or Geography
| Products and services | $30.09M | 97.29% |
| Other | $815.00K | 2.64% |
| COVID-19 | $22.00K | 0.07% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New OSUR patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to OSUR from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from OSUR’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 2026 earnings show double-digit YoY growth and margin expansion; activist pressure resolved constructively through agreement with Altai Capital.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| GERM | ETFMG Treatments, Testing and Advancements ETF | 0.73% |
| QQQS | Invesco NASDAQ Future Gen 200 ETF | 0.56% |
| BUSM | EA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | 0.28% |
| PQSG | PGIM ETF Trust - PGIM QMA Strategic Alpha Small-Cap Growth ETF | 0.18% |
| PQSV | PGIM ETF Trust - PGIM QMA Strategic Alpha Small-Cap Value ETF | 0.12% |
| DMRS | DeltaShares S&P 600 Managed Risk ETF | 0.09% |
| IWC | iShares Micro-Cap ETF | 0.06% |
| SLY | SPDR S&P 600 Small Cap ETF | 0.05% |
| JPSE | JPMorgan Diversified Return U.S. Small Cap Equity ETF | 0.04% |
| MSSM | Morgan Stanley Pathway Funds - Small-Mid Cap Equity ETF | 0.04% |
| PKW | Invesco BuyBack Achievers ETF | 0.01% |
| VHT | Vanguard Health Care ETF | 0.00% |
Weight is the stock’s share of each fund’s holdings.
